Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Spatiotemporal regulation of clonogenicity in colorectal cancer xenografts.

van der Heijden M, Miedema DM, Waclaw B, Veenstra VL, Lecca MC, Nijman LE, van Dijk E, van Neerven SM, Lodestijn SC, Lenos KJ, de Groot NE, Prasetyanti PR, Arricibita Varea A, Winton DJ, Medema JP, Morrissey E, Ylstra B, Nowak MA, Bijlsma MF, Vermeulen L.

Proc Natl Acad Sci U S A. 2019 Mar 8. pii: 201813417. doi: 10.1073/pnas.1813417116. [Epub ahead of print]

2.

Cancer stem cells: here, there, and everywhere.

Lodestijn SC, Lenos KJ, Miedema DM, Bijlsma MF, Vermeulen L.

Mol Cell Oncol. 2018 Dec 4;6(1):1540235. doi: 10.1080/23723556.2018.1540235. eCollection 2019.

PMID:
30788417
3.

Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial.

van Hilst J, de Rooij T, Bosscha K, Brinkman DJ, van Dieren S, Dijkgraaf MG, Gerhards MF, de Hingh IH, Karsten TM, Lips DJ, Luyer MD, Busch OR, Festen S, Besselink MG; Dutch Pancreatic Cancer Group.

Lancet Gastroenterol Hepatol. 2019 Mar;4(3):199-207. doi: 10.1016/S2468-1253(19)30004-4. Epub 2019 Jan 24.

PMID:
30685489
4.

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma.

Ebbing EA, van der Zalm AP, Steins A, Creemers A, Hermsen S, Rentenaar R, Klein M, Waasdorp C, Hooijer GKJ, Meijer SL, Krishnadath KK, Punt CJA, van Berge Henegouwen MI, Gisbertz SS, van Delden OM, Hulshof MCCM, Medema JP, van Laarhoven HWM, Bijlsma MF.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2237-2242. doi: 10.1073/pnas.1820459116. Epub 2019 Jan 22.

5.

ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.

Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF.

Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9.

6.

Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice: comment.

Spek CA, Tekin C, Bijlsma MF.

J Thromb Haemost. 2019 Jan;17(1):235-238. doi: 10.1111/jth.14329. Epub 2018 Dec 4. No abstract available.

PMID:
30412650
7.

Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study.

Campa D, Matarazzi M, Greenhalf W, Bijlsma M, Saum KU, Pasquali C, van Laarhoven H, Szentesi A, Federici F, Vodicka P, Funel N, Pezzilli R, Bueno-de-Mesquita HB, Vodickova L, Basso D, Obazee O, Hackert T, Soucek P, Cuk K, Kaiser J, Sperti C, Lovecek M, Capurso G, Mohelnikova-Duchonova B, Khaw KT, König AK, Kupcinskas J, Kaaks R, Bambi F, Archibugi L, Mambrini A, Cavestro GM, Landi S, Hegyi P, Izbicki JR, Gioffreda D, Zambon CF, Tavano F, Talar-Wojnarowska R, Jamroziak K, Key TJ, Fave GD, Strobel O, Jonaitis L, Andriulli A, Lawlor RT, Pirozzi F, Katzke V, Valsuani C, Vashist YK, Brenner H, Canzian F.

Int J Cancer. 2019 Mar 15;144(6):1275-1283. doi: 10.1002/ijc.31928. Epub 2018 Nov 12.

PMID:
30325019
8.

Multidrug-resistant transporter expression does not always result in drug resistance.

Le Large TYS, El Hassouni B, Kazemier G, Piersma SR, van Laarhoven HWM, Bijlsma MF, Jimenez CR, Giovannetti E.

Cancer Sci. 2018 Oct;109(10):3360-3362. doi: 10.1111/cas.13756. Epub 2018 Sep 8. No abstract available.

9.

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.

Creemers A, Ebbing EA, Pelgrim TC, Lagarde SM, van Etten-Jamaludin FS, van Berge Henegouwen MI, Hulshof MCCM, Krishnadath KK, Meijer SL, Bijlsma MF, van Oijen MGH, van Laarhoven HWM.

Sci Rep. 2018 Sep 5;8(1):13281. doi: 10.1038/s41598-018-31548-6.

10.

Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer.

Lenos KJ, Miedema DM, Lodestijn SC, Nijman LE, van den Bosch T, Romero Ros X, Lourenço FC, Lecca MC, van der Heijden M, van Neerven SM, van Oort A, Leveille N, Adam RS, de Sousa E Melo F, Otten J, Veerman P, Hypolite G, Koens L, Lyons SK, Stassi G, Winton DJ, Medema JP, Morrissey E, Bijlsma MF, Vermeulen L.

Nat Cell Biol. 2018 Oct;20(10):1193-1202. doi: 10.1038/s41556-018-0179-z. Epub 2018 Sep 3.

11.

PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer.

Tekin C, Shi K, Daalhuisen JB, Ten Brink MS, Bijlsma MF, Spek CA.

Oncotarget. 2018 Aug 10;9(62):32010-32023. doi: 10.18632/oncotarget.25880. eCollection 2018 Aug 10.

12.

The dynamics of HER2 status in esophageal adenocarcinoma.

Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM.

Oncotarget. 2018 Jun 1;9(42):26787-26799. doi: 10.18632/oncotarget.25507. eCollection 2018 Jun 1.

13.

The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma.

Houg DS, Bijlsma MF.

Mol Cancer. 2018 Jun 14;17(1):95. doi: 10.1186/s12943-018-0842-9. Review.

14.

Patched-2 functions to limit Patched-1 deficient skin cancer growth.

Veenstra VL, Dingjan I, Waasdorp C, Damhofer H, van der Wal AC, van Laarhoven HW, Medema JP, Bijlsma MF.

Cell Oncol (Dordr). 2018 Aug;41(4):427-437. doi: 10.1007/s13402-018-0381-9. Epub 2018 Jun 4.

15.

Molecular subtyping of cancer: current status and moving toward clinical applications.

Zhao L, Lee VHF, Ng MK, Yan H, Bijlsma MF.

Brief Bioinform. 2018 Apr 12. doi: 10.1093/bib/bby026. [Epub ahead of print]

PMID:
29659698
16.

The Dutch Pancreas Biobank Within the Parelsnoer Institute: A Nationwide Biobank of Pancreatic and Periampullary Diseases.

Strijker M, Gerritsen A, van Hilst J, Bijlsma MF, Bonsing BA, Brosens LA, Bruno MJ, van Dam RM, Dijk F, van Eijck CH, Farina Sarasqueta A, Fockens P, Gerhards MF, Groot Koerkamp B, van der Harst E, de Hingh IH, van Hooft JE, Huysentruyt CJ, Kazemier G, Klaase JM, van Laarhoven CJ, van Laarhoven HW, Liem MS, de Meijer VE, van Rijssen LB, van Santvoort HC, Suker M, Verhagen JH, Verheij J, Verspaget HW, Wennink RA, Wilmink JW, Molenaar IQ, Boermeester MA, Busch OR, Besselink MG; Dutch Pancreatitis Study Group and Dutch Pancreatic Cancer Group.

Pancreas. 2018 Apr;47(4):495-501. doi: 10.1097/MPA.0000000000001018.

PMID:
29521943
17.

Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer.

Veenstra VL, Garcia-Garijo A, van Laarhoven HW, Bijlsma MF.

Cancers (Basel). 2018 Jan 27;10(2). pii: E34. doi: 10.3390/cancers10020034. Review.

18.

Epigenetic regulation of the Hedgehog and Wnt pathways in cancer.

Wils LJ, Bijlsma MF.

Crit Rev Oncol Hematol. 2018 Jan;121:23-44. doi: 10.1016/j.critrevonc.2017.11.013. Epub 2017 Nov 24. Review.

19.

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.

Steins A, Ebbing EA, Pistorius MCM, Waasdorp C, Krishnadath KK, Medema JP, Wilmink JW, Mathôt RAA, Bijlsma MF, van Laarhoven HWM.

Drug Deliv. 2017 Nov;24(1):1801-1810. doi: 10.1080/10717544.2017.1406559.

PMID:
29172757
20.

Skin-Derived Vitamin D3 Protects against Basal Cell Carcinoma.

Bijlsma MF, Roelink H.

J Invest Dermatol. 2017 Dec;137(12):2469-2471. doi: 10.1016/j.jid.2017.07.816.

Supplemental Content

Loading ...
Support Center